Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 168

Similar articles for PubMed (Select 19636338)

1.

Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.

Laika B, Leucht S, Heres S, Schneider H, Steimer W.

Pharmacogenomics J. 2010 Feb;10(1):20-9. doi: 10.1038/tpj.2009.32. Epub 2009 Jul 28.

PMID:
19636338
2.

Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study.

Ujike H, Nomura A, Morita Y, Morio A, Okahisa Y, Kotaka T, Kodama M, Ishihara T, Kuroda S.

J Clin Psychiatry. 2008 Sep;69(9):1416-22.

PMID:
19193342
3.

Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine.

Gunes A, Melkersson KI, Scordo MG, Dahl ML.

J Clin Psychopharmacol. 2009 Feb;29(1):65-8. doi: 10.1097/JCP.0b013e31819302c3.

PMID:
19142110
4.

The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP).

Nozawa M, Ohnuma T, Matsubara Y, Sakai Y, Hatano T, Hanzawa R, Shibata N, Arai H.

Ther Drug Monit. 2008 Feb;30(1):35-40. doi: 10.1097/FTD.0b013e31816336fd.

PMID:
18223460
5.

Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting.

Alenius M, Wadelius M, Dahl ML, Hartvig P, Lindström L, Hammarlund-Udenaes M.

J Psychiatr Res. 2008 Sep;42(11):884-93. Epub 2007 Dec 20.

PMID:
18086475
6.

CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations.

Czerwensky F, Leucht S, Steimer W.

Ther Drug Monit. 2015 Apr;37(2):152-60. doi: 10.1097/FTD.0000000000000119.

PMID:
25090458
7.

Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients.

Gunes A, Scordo MG, Jaanson P, Dahl ML.

Psychopharmacology (Berl). 2007 Mar;190(4):479-84. Epub 2006 Nov 11.

PMID:
17102980
8.

The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia.

Lin YC, Ellingrod VL, Bishop JR, Miller DD.

Ther Drug Monit. 2006 Oct;28(5):668-72.

PMID:
17038883
9.

Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and olanzapine-induced weight gain among Korean schizophrenic patients.

Park YM, Cho JH, Kang SG, Choi JE, Lee SH, Kim L, Lee HJ.

J Clin Pharm Ther. 2008 Feb;33(1):55-60. doi: 10.1111/j.1365-2710.2008.00872.x.

PMID:
18211617
10.

Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure--an impact similar to male gender or smoking in schizophrenic patients.

Ghotbi R, Mannheimer B, Aklillu E, Suda A, Bertilsson L, Eliasson E, Osby U.

Eur J Clin Pharmacol. 2010 May;66(5):465-74. doi: 10.1007/s00228-009-0783-8. Epub 2010 Feb 9.

PMID:
20143052
11.

Effect of serotonin receptor 2A gene polymorphism on mirtazapine response in major depression.

Kang RH, Choi MJ, Paik JW, Hahn SW, Lee MS.

Int J Psychiatry Med. 2007;37(3):315-29.

PMID:
18314859
12.

The cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patients.

Kootstra-Ros JE, Smallegoor W, van der Weide J.

Ann Clin Biochem. 2005 May;42(Pt 3):216-9.

PMID:
15949157
13.
14.

Influence of CYP1A1/CYP1A2 and AHR polymorphisms on systemic olanzapine exposure.

Söderberg MM, Haslemo T, Molden E, Dahl ML.

Pharmacogenet Genomics. 2013 May;23(5):279-85. doi: 10.1097/FPC.0b013e3283602876.

PMID:
23492908
15.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
16.

Association of serotonin 2A receptor and lack of association of CYP1A2 gene polymorphism with tardive dyskinesia in a Turkish population.

Boke O, Gunes S, Kara N, Aker S, Sahin AR, Basar Y, Bagci H.

DNA Cell Biol. 2007 Aug;26(8):527-31.

PMID:
17688403
17.

The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients.

Kuzman MR, Medved V, Bozina N, Hotujac L, Sain I, Bilusic H.

Psychiatry Res. 2008 Sep 30;160(3):308-15. doi: 10.1016/j.psychres.2007.06.006. Epub 2008 Aug 20.

PMID:
18718676
18.

Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients.

Bondolfi G, Morel F, Crettol S, Rachid F, Baumann P, Eap CB.

Ther Drug Monit. 2005 Aug;27(4):539-43.

PMID:
16044115
19.

Influence of the genetic polymorphism in the 5'-noncoding region of the CYP1A2 gene on CYP1A2 phenotype and urinary mutagenicity in smokers.

Pavanello S, Pulliero A, Lupi S, Gregorio P, Clonfero E.

Mutat Res. 2005 Nov 10;587(1-2):59-66. Epub 2005 Sep 26.

PMID:
16188490
20.

ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.

Jaquenoud Sirot E, Knezevic B, Morena GP, Harenberg S, Oneda B, Crettol S, Ansermot N, Baumann P, Eap CB.

J Clin Psychopharmacol. 2009 Aug;29(4):319-26. doi: 10.1097/JCP.0b013e3181acc372.

PMID:
19593168
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk